Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606567 | 1.00 | CFD (0.40) | CFDGAAL3MBTL1ADRB2CYP2D6 | |
| SCHEMBL26599214 | 0.94 | GAA (0.49) | CFDGAAL3MBTL1ADRB2CYP2D6 | |
| SCHEMBL30606572 | 0.94 | GAA (0.49) | CFDGAAL3MBTL1ADRB2CYP2D6 | |
| SCHEMBL1198192 | 0.89 | ALDH1A1 (0.45) | CFDALDH1A1KMT2A | |
| SCHEMBL8263707 | 0.83 | L3MBTL1 (0.49) | GAAL3MBTL1ADRB2CYP2D6CYP3A4 | |
| SCHEMBL31174638 | 0.81 | GAA (0.40) | GAAL3MBTL1ADRB2CYP2D6 | |
| SCHEMBL26598995 | 0.81 | GAA (0.40) | GAAL3MBTL1ADRB2CYP2D6 | |
| SCHEMBL26666993 | 0.80 | CFD (0.40) | CFD | |
| SCHEMBL30606589 | 0.79 | CFD (0.36) | CFDALDH1A1GLAKMT2A | |
| SCHEMBL30606504 | 0.78 | CFD (0.35) | CFDGLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4511355-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FundaMental Pharma GmbH (DE) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024223617-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | TRPM4, GRM4, GRIN1 | CFD 4489/4885GAA 1666/4885L3MBTL1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.